Study of IMC-S118AI in Type 1 Diabetes

Starting soon · Phase 1

Conditions studied: Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1

In brief

This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.

Key facts

Study ID

NCT07493122

Run by

Immunocore Ltd

People needed

154

Starts

2026-04-01

Expected to finish

2030-11-01

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI): 18 to 25 kg/m2
• History of a diagnosis of T1D
• HLA type: HLA-A*02:01
• Shows signs of remaining beta-cell function

You may not qualify if…

• Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes)
• History of recurrent hypoglycaemia due to non-compliance with insulin regimens
• Prior treatment with immunomodulating therapy for T1D
• Have a history of cardiovascular disease or impaired cardiac function
• Current diagnosis of a malignancy or any history of malignancy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.